VitaNova Life Sciences (VNOV) Cash & Equivalents (2017 - 2026)

VitaNova Life Sciences (VNOV) has 9 years of Cash & Equivalents data on file, last reported at $1.6 million in Q2 2026.

• Quarterly Cash & Equivalents rose 104.04% year-over-year to $1.6 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.6 million (up 104.04% YoY) and the FY2026 annual result came in at $1.6 million, up 104.04% from the prior year.
• Cash & Equivalents rose to $1.6 million in Q2 2026, from $1.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.6 million in Q2 2026 to a low of $8728.0 in Q2 2023.
• A 5-year average of $510730.0 and a median of $313984.0 in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 70.18% — and 2024, when it soared 7240.02%.
• Tracing VNOV's Cash & Equivalents over 5 years: stood at $36190.0 in 2022, then slumped by 75.88% to $8728.0 in 2023, then soared by 2452.65% to $222795.0 in 2024, then jumped by 465.22% to $1.3 million in 2025, then gained by 26.84% to $1.6 million in 2026.
• The last three Cash & Equivalents figures came in at $1.6 million (Q2 2026), $1.2 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.